quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:17:17·9d
ANALYSTRating
Travere Therapeutics Inc. logo

Travere Therapeutics upgraded by Piper Sandler with a new price target

TVTX· Travere Therapeutics Inc.
Health Care
Original source

Companies

  • TVTX
    Travere Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 14UpdatePiper Sandler$49.00
  • Oct 31UpdateCitigroup$48.00
  • Jun 11UpdateH.C. Wainwright$30.00
  • Jun 11UpdateCitigroup$32.00
  • Jan 10UpdateCantor Fitzgerald-
  • Oct 21UpdateWells Fargo$27.00

Related

  • INSIDER10h
    Chief Research Officer Rote William E. sold $355,719 worth of shares (9,100 units at $39.09) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 113,987 units (SEC Form 4)
  • INSIDER7d
    SEC Form 4 filed by Baynes Roy D.
  • INSIDER7d
    SEC Form 4 filed by Lyons Gary A
  • INSIDER7d
    SEC Form 4 filed by Calvin Sandra
  • INSIDER8d
    SEC Form 4 filed by Heerma Peter
  • INSIDER8d
    SEC Form 4 filed by Rote William E.
  • INSIDER8d
    SEC Form 4 filed by Dube Eric M
  • INSIDER8d
    SEC Form 4 filed by Reed Elizabeth E
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022